BridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1
22 déc. 2022 07h30 HE
|
BridgeBio Pharma, Inc.
- The CALIBRATE Phase 3 study design incorporates feedback from global regulatory agencies and will compare the effects of encaleret to standard of care on blood and urinary calcium concentrations...
BridgeBio Pharma to Participate in November Investor Events
09 nov. 2022 07h30 HE
|
BridgeBio Pharma, Inc.
PALO ALTO, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases...
BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update
03 nov. 2022 07h30 HE
|
BridgeBio Pharma, Inc.
- Reported positive preclinical data for its next-generation KRASG12C GTP/GDP dual inhibitor development candidate, BBO-8520, and for its novel PI3Kα:RAS breaker mechanism in late lead optimization -...
BridgeBio Pharma Highlights its RAS Precision Oncology Portfolio and Shares Compelling Data from Next-generation G12C Inhibitor and Novel PI3Kα:RAS Breaker Mechanism at the Fourth RAS Initiative Symposium
17 oct. 2022 12h30 HE
|
BridgeBio Pharma, Inc.
- BridgeBio to host investor call today (October 17, 2022) at 1:30 pm ET to discuss its two most advanced RAS precision oncology programs – KRASG12C GTP/GDP dual inhibitor development candidate...
BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)
14 oct. 2022 07h30 HE
|
BridgeBio Pharma, Inc.
Novel assay developed to assess the extent of alpha-dystroglycan (⍺DG) glycosylation, the core pathology of LDMD2i, from muscle biopsy samplesIncrease in the ratio of glycosylated αDG to total αDG...
BridgeBio Pharma Presents Updated Positive Data from its BBP-812 Canavan Disease Gene Therapy Program at the 51st Annual Meeting of the Child Neurology Society
13 oct. 2022 16h00 HE
|
BridgeBio Pharma, Inc.
- Robust post-dosing changes continue to be seen in key markers associated with severity of disease - Pharmacodynamic data from the first three participants show sustained reductions in...
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen’s LUMAKRAS® (sotorasib)
11 oct. 2022 07h30 HE
|
BridgeBio Pharma, Inc.
- BBP-398, an investigational SHP2 inhibitor, is a potentially optimal agent for use in combination therapies given its continuous, once-daily dosing in addition to synergistic activity with other...
BridgeBio Pharma to Present New Data on its Novel Approaches to RAS-driven Cancers at the Fourth RAS Initiative Symposium
07 oct. 2022 07h30 HE
|
BridgeBio Pharma, Inc.
- The conference will take place at the National Cancer Institute at Frederick, Maryland from October 17-19, 2022 - Presentation to include details from next-generation G12C dual inhibitor clinical...
BridgeBio Pharma and Sentynl Therapeutics Receive Marketing Authorization in the EU for NULIBRY® (fosdenopterin) for the Treatment of MoCD Type A
20 sept. 2022 07h30 HE
|
BridgeBio Pharma, Inc.
- The first and only treatment in Europe to treat patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that often progresses rapidly in infants...
BridgeBio Pharma to Participate in September Investor Events
06 sept. 2022 07h30 HE
|
BridgeBio Pharma, Inc.
PALO ALTO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases...